News
- Elanco Announces Agreement to Acquire Kindred BiosciencesJune 16, 2021 6:30 AM EDT
- Kindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal Antibody for the Prevention of Deaths in Dogs Infected by ParvovirusJune 2, 2021 8:31 AM EDT
- Kindred Biosciences to Present at Stifel 2021 Virtual Jaws & Paws Conference and LD Micro Invitational XIMay 25, 2021 8:42 AM EDT
Events
- Tuesday, June 8, 2021 from 1:30 PM to 1:55 PM EDT
- Wednesday, June 2, 2021 from 11:00 AM to 11:25 AM EDT
- Tuesday, May 11, 2021 4:30 PM EDT
|
KindredBio proudly supports
Rabies Free Africa
Corporate Profile
KindredBio is focused on bringing innovative biologics and technologies to veterinary medicine to address unmet clinical needs and provide benefits to pets.
The Approach
We identify biologics and targets that have been validated in humans and develop animal versions to treat and cure pets. We seek to leverage the investments that have been made in human pharmaceutical R&D to develop therapies for pets with lower risk, lower cost, and shorter time-to-market, compared to human drug development.
The Opportunity
We believe KindredBio can deliver superior returns to investors because while the market sizes for pet drugs are about 2-fold to 10-fold smaller compared to human market sizes, the cost of development is 100-fold less.
World Class Team
KindredBio is one of the first pet biotechs in the world, and we have a world-class team including the former Head of Biotherapeutics Clinical Research at Genentech. We also have expertise in many cutting-edge antibody technologies. Because of the team, and because we do not outsource our clinical studies, we can move at a very rapid pace.
Contact Us
To contact investor relations, or to request an investor packet, please call 917.969.3438 or email IR@kindredbio.com.